Platelet counts and haemorrhagic diathesis in patients with myelodysplastic syndromes

Objectives:  Most patients with myelodysplastic syndromes (MDS) present with single or multiple lineage cytopenias in peripheral blood despite a hypercellular bone marrow. Thrombocytopenia, attributable to ineffective platelet production by dysfunctional megakaryocytes, has been estimated to occur in 40–65% of patients. However, there are hardly any studies on the clinical relevance of low platelet counts in MDS.

[1]  J. Issa,et al.  Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System , 2008, Cancer.

[2]  U. Germing,et al.  Platelet morphology, platelet mass, platelet count and prognosis in patients with myelodysplastic syndromes , 2007, British journal of haematology.

[3]  H. Kantarjian,et al.  The incidence and impact of thrombocytopenia in myelodysplastic syndromes , 2007, Cancer.

[4]  T. Baglin,et al.  Platelet mass has prognostic value in patients with myelodysplastic syndromes , 2006, British journal of haematology.

[5]  U. Germing,et al.  Prospective validation of the WHO proposals for the classification of myelodysplastic syndromes. , 2006, Haematologica.

[6]  U. Germing,et al.  No increase in age-specific incidence of myelodysplastic syndromes. , 2004, Haematologica.

[7]  A. Ganser,et al.  Evaluating the prognosis of patients with myelodysplastic syndromes , 2002, Annals of Hematology.

[8]  W. Hofmann,et al.  Defective Megakaryocytic Development in Myelodysplastic Syndromes , 2000, Leukemia & lymphoma.

[9]  G Flandrin,et al.  The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  A. Houtsmuller,et al.  Cytogenetic clonality analysis of megakaryocytes in myelodysplastic syndrome by dual‐color fluorescence in situ hybridization and confocal laser scanning microscopy , 1999, Genes, chromosomes & cancer.

[11]  P. Greenberg,et al.  Prognostic factors and scoring systems in myelodysplastic syndromes. , 1998, Haematologica.

[12]  T Hamblin,et al.  International scoring system for evaluating prognosis in myelodysplastic syndromes. , 1997, Blood.

[13]  H. Gralnick,et al.  Proposals for the classification of the myelodysplastic syndromes , 1982, British journal of haematology.